From the publishers of JADPRO

MPN Resource Center

Advertisement

Future of myelofibrosis treatment is moving beyond just JAK inhibition

Last Updated: Tuesday, March 29, 2022

This article showcases a presentation from the 26th Annual International Congress on Hematologic Malignancies on new treatment modalities for myelofibrosis, including BET, BCL-2/BCL-XL, PI3K, MDM2 inhibition and telomerase.

OncLive
Advertisement
News & Literature Highlights
Advertisement
Advertisement